Cover |
Aug. 05, 2026 |
|---|---|
| Cover [Abstract] | |
| Document Type | 8-K/A |
| Amendment Flag | true |
| Amendment Description | On August 6, 2026, Ensysce Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” or the “Company”), filed a Current Report on Form 8-K with the Securities and Exchange Commission (the “Original 8-K”), which reported information under Items 1.01, 2.01, 3.02, 3.03, 5.02, 5.03, 7.01 and 9.01 of Form 8-K. This Current Report on Form 8-K/A (i) files Exhibit 3.3, a Certificate of Correction related to Exhibit 3.2 in the Original 8-K, (ii) files a corrected press release as Exhibit 99.1 and (iii) corrects, from $100,000 to $200,000, a fee identified under Item 1.01 paid to Tungsten Partners LLC. This Current Report on Form 8-K/A should be read in conjunction with the Original 8-K. Except as set forth herein, no modifications have been made to information contained in the Original 8-K |
| Document Period End Date | Aug. 05, 2026 |
| Entity File Number | 001-38306 |
| Entity Registrant Name | Ensysce Biosciences, Inc. |
| Entity Central Index Key | 0001716947 |
| Entity Tax Identification Number | 82-2755287 |
| Entity Incorporation, State or Country Code | DE |
| Entity Address, Address Line One | 7946 Ivanhoe Avenue |
| Entity Address, Address Line Two | Suite 201 |
| Entity Address, City or Town | La Jolla |
| Entity Address, State or Province | CA |
| Entity Address, Postal Zip Code | 92037 |
| City Area Code | (858) |
| Local Phone Number | 263-4196 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share |
| Trading Symbol | ENSC |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |
| Entity Information, Former Legal or Registered Name | N/A |